DeepRx Inc. Appoints Mr. Wensheng Fan as CEO for the AI in Precision Oncology Company
Accomplished Technology Executive and Entrepreneur Wensheng Fan Joins DeepRx Inc.
PITTSBURGH, PENNSYLVANIA / ACCESS Newswire / March 11, 2025 / DeepRx Inc., a predictive analytics company advancing AI-driven solutions for precision oncology, is pleased to announce the appointment of Wensheng Fan as its new Chief Executive Officer.
As CEO of DeepRx, Wensheng Fan will guide DeepRx in the commercialization of COLOXIS, an AI-powered chemotherapy drug-selection tool, which optimizes treatment for colorectal cancer patients.
Wensheng Fan joins DeepRx as an accomplished technology executive and entrepreneur with over three decades of experience in leading high-tech product development. For the past 15 years, he co-founded and led Spectral AI, driving the development of DeepView®, an FDA Breakthrough-designated diagnostic technology. As CEO, Wensheng Fan secured over $250 million in U.S. federal contracts and $39 million in commercial funding. He led the company IPO on the London Stock Exchange in 2021 and later transitioned it to NASDAQ Global Market in 2023, demonstrating his ability to scale and commercialize groundbreaking AI technologies in medicine.
Before Spectral AI, Wensheng Fan played pivotal roles in start-ups and large, international companies, including imaging technologies for self-driving cars at Sensata Technologies; broadband wireless communications at Navini Networks (acquired by Cisco); and as an early core member of PureSpeech Inc., a natural speech recognition technology company later acquired by Phillips.
Mr. Fan earned his M.S. in Electrical Engineering from Northeastern University in Boston, MA, and B.S. in Electrical Engineering from Tsinghua University in Beijing, China.
Wensheng Fan, Chief Executive Officer of DeepRx, said, 'I am honored to join DeepRx at such a pivotal moment to commercialize COLOXIS. I am dedicated to leading DeepRx in delivering AI-driven solutions that support oncologists and improve care for cancer patients.'
Prof. Xinghua Lu, MD, PhD, co-founder and Chief Science Officer of DeepRx, said, 'We are thrilled to welcome Mr. Wensheng Fan as our new CEO. His proven track record in advancing transformative technologies will be invaluable as we push the boundaries of AI in precision oncology. With his leadership, we are confident DeepRx will bring COLOXIS to oncologists, empowering them to make more precise, informed decisions for the benefit of colorectal cancer patients worldwide.'
DeepRx is committed to leveraging artificial intelligence to revolutionize personalized medicine, and Wensheng Fan's expertise in AI-driven healthcare solutions aligns seamlessly with the company's mission. His leadership will accelerate the development and deployment of COLOXIS, ensuring oncologists have access to state-of-the-art tools to enhance clinical decision-making.
About DeepRx:
DeepRx is an innovative healthcare technology company focused on developing AI-powered solutions to optimize cancer treatment. Its first flagship product, COLOXIS, utilizes advanced algorithms to assist oncologists in selecting the most effective chemotherapy drugs for colorectal cancer patients. COLOXIS was successfully double-blind tested in 1,065 colorectal cancer samples, with the outcome published in the Journal of Clinical Oncology. By harnessing AI, DeepRx aims to enhance precision medicine and improve patient care outcomes worldwide.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Ancora Heart Inc. Reaches First Enrollment Milestone in CORCINCH-HF Heart Failure Pivotal Trial
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), today announced that it has reached the first enrollment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch ® Transcatheter Left Ventricular Restoration System in patients with heart failure with reduced ejection fraction (HFrEF). Six-month follow-up data on these 250 patients will support the company's Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA). 'The AccuCinch System is the only completely transcatheter procedure to treat the enlarged left ventricle. Reaching this milestone is an incredible accomplishment in heart failure research." - Jeff Closs, president and CEO, Ancora Heart Share The AccuCinch System is an investigational device designed to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. Results from early clinical studies were presented at the 2023 Technology and Heart Failure Therapeutics conference and simultaneously published in the Journal of Cardiac Failure. The AccuCinch System was granted Breakthrough Device Designation from the FDA in 2022. 'The AccuCinch System is the only completely transcatheter procedure to treat the enlarged left ventricle,' said Jeff Closs, president and CEO of Ancora Heart. 'Reaching this milestone is an incredible accomplishment in heart failure research and a model example of collaboration across heart failure and structural heart care teams at participating CORCINCH-HF clinical trial sites. We'd like to thank study investigators for their commitment to innovation and partnership, and we look forward to building on this momentum as we work toward reaching our full enrollment target of 400 patients.' The CORCINCH-HF study is evaluating the safety and effectiveness of the AccuCinch System in patients who have symptomatic HF with reduced ejection fraction. An estimated 6.7 million adults in the U.S. live with heart failure, and about half have HFrEF. 1,2 'Despite advances in guideline-directed medical therapy, many patients with heart failure continue to experience debilitating symptoms,' said Ulrich Jorde, MD, global co-principal investigator of the CORCINCH-HF Study, professor of medicine, Albert Einstein College of Medicine, and section head of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support at Montefiore Health System in New York. 'Reaching this milestone in the CORCINCH-HF study is a significant step toward determining whether this treatment option may improve the length and quality of their lives.' 'AccuCinch is a device-based therapy aimed at reverse remodeling of the enlarged left ventricle,' said Mark Reisman, MD*, global co-principal investigator of the CORCINCH-HF Study, director of structural heart disease at NewYork-Presbyterian/Weill Cornell Medical Center and co-director of structural heart disease for NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital, who was recruited to Weill Cornell Medicine as a professor of medicine. 'This trial is designed to evaluate the safety of the device and procedure and whether we can improve heart structure and function and thereby help patients feel better, avoid hospitalizations and live longer.' About Heart Failure An estimated 6.7 million adults in the U.S. live with heart failure, a condition in which the heart's muscles weaken and lose their ability to pump enough oxygen-rich blood to the body. 1,2 Heart failure patients suffer from debilitating symptoms, including persistent exhaustion, trouble breathing and confusion, as well as frequent hospitalizations. About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency. Up to 50% of people who develop heart failure die within five years of diagnosis. 3 About the AccuCinch ® Transcatheter Left Ventricular Restoration System The AccuCinch System is an investigational device designed to augment the existing care cardiologists provide their heart failure patients. For patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant. During the minimally invasive AccuCinch System procedure, a flexible implant is attached to the inner wall of the left ventricle and then cinched. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. The AccuCinch System is under clinical evaluation to determine its potential benefits related to patient symptoms, quality of life and life expectancy. About the CORCINCH-HF Study The CORCINCH-HF Study (NCT04331769) is a prospective, randomized, open-label, multicenter, international, clinical safety and effectiveness investigation of the AccuCinch Transcatheter Left Ventricular Restoration System, which is designed to enroll 400 patients at centers worldwide. The study has a unique design allowing initial analysis of safety and clinical effectiveness for PMA submission after the first 250 patients have reached six months of follow-up, and then a second analysis after the entire cohort has reached 12 months of follow-up. About Ancora Heart, Inc. Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF). The company's lead product is the AccuCinch ® Transcatheter Left Ventricular Restoration System, an investigational device currently being studied in the CORCINCH-HF pivotal trial. Ancora Heart is a privately held company located in Santa Clara, Calif. For more information, about Ancora Heart and its products, visit and follow the company on Facebook, LinkedIn and X. * Dr. Reisman reports travel support from Ancora Heart. 1 Martin SS, Aday AW, Almarzooq ZI, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee; Stroke Statistics Subcommittee. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347–913. 2 Murphy S, Ibrahim N, Januzzi J. Heart Failure with Reduced Ejection Fraction, A Review. JAMA. 2020;324(5):488-504 3 Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-596.
Business Wire
an hour ago
- Business Wire
One, Two, Three-Peat: Mary Kay Inc. Named #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World for Three Years in a Row
DALLAS--(BUSINESS WIRE)--Good things come in threes: iconic beauty brand and global entrepreneurship company Mary Kay Inc. has again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World 1 by Euromonitor International for the third consecutive year. Mary Kay products are sold by best-in-class Independent Beauty Consultants who provide personalized service to customers in person and online at and on social and digital media channels. Share Euromonitor International is the foremost provider of global business intelligence, market analysis, and consumer insights with over 50 years of conducting market research across more than 100 countries. "Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay,' said Ryan Rogers, Chief Executive Officer of Mary Kay. 'This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally." In addition to the global recognition, Mary Kay has been named: #1 Brand of Facial Make-Up in Latin America,* #1 Brand of Lip Products in Latin America,* #1 Brand of Color Cosmetics in Mexico,* #1 Brand of Skincare and Color Cosmetics in Mexico.* Sarah Boumphrey, Global Research Director at Euromonitor International, stated, 'Our awards reflect the highest standard of excellence in the industries we track, and beauty and direct selling are no exception. Honorees are recognized through a rigorous, data-driven evaluation process that draws on independent research, global market analysis, and deep category expertise. Euromonitor is proud to collaborate with leading companies, like Mary Kay, and this accomplishment signifies their commitment to performance and quality in a highly competitive landscape." With presence in over 40 markets and millions of Independent Beauty Consultants around the world, Mary Kay continues to set the standard for beauty that empowers and delivers. Several fan-favorite products contribute to Mary Kay's #1 status, including the iconic TimeWise ® skincare line, the dermatologist validated Clinical Solutions ® skincare line, the Mary Kay ® Oil-Free Eye Makeup Remover beloved by influencers and celebrities, the Mary Kay ® Ultimate Mascara™, the Mary Kay Unlimited ® Lip Gloss, and the Mary Kay ® Waterproof Eyeliner, to name a few. In 2024 alone, Mary Kay garnered 65 beauty awards around the world. In addition to the Euromonitor International #1 recognition, Mary Kay recently ranked #11 in the Women's Wear Daily Beauty Inc.'s 2024 Top 100 Beauty Companies. Mary Kay products are sold by best-in-class Independent Beauty Consultants who provide personalized service to customers in person and online at and on social and digital media channels. The Euromonitor award reinforces Mary Kay as one of the world's best loved brands with a business model and corporate mission focused on empowering women, transforming lives, and helping to protect our natural resources. Did You Know: One Mary Kay ® Oil-Free Eye Makeup Remover is sold every 5 minutes around the globe. 2 Nearly 1,500 patents globally are held by Mary Kay for products, technologies, and packaging designs in its global portfolio. 3 Mary Kay's state-of-the-art Richard R. Rogers (R3) global Manufacturing/R&D Center located in Lewisville, Texas, has a production capacity of up to 1.1 million products per day. 62% of Mary Kay's global R&D teams are women. 4 81% of Mary Kay's Global Marketing team & Creative Studio are women. 5 30% of sales force members who started their Mary Kay business in the past year are under the age of 35. 6 About Mary Kay One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women's lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at Find us on Facebook, Instagram, and LinkedIn, or follow us on X.
Business Wire
3 hours ago
- Business Wire
CTC Global Appoints Charles Girard as Director of Business Development, International Finance
IRVINE, Calif.--(BUSINESS WIRE)--CTC Global, the world's leading developer and manufacturer of high-capacity advanced conductors, is pleased to announce the addition of Charles Girard who has joined its global sales and business development team as Director, Business Development, International Finance. In this new role, Mr. Girard will lead market development efforts and help drive global adoption of CTC Global's advanced ACCC® Conductor technology by engaging with major international financial institutions, including the World Bank, Asian Development Bank, African Development Bank, U.S. EXIM Bank, and similar organizations. 'Charles brings a wealth of experience and a deep understanding of international energy markets, infrastructure financing, and policy,' said David Chiesa, CTC Global's Vice President of International Sales and Business Development. 'Charles' global perspective and proven track record in project development and institutional engagement will help drive continued support from these important investors in grid capacity, efficiency and resiliency.' Prior to joining CTC Global, Mr. Girard served as a senior advisor at the World Bank, where he oversaw more than $3 billion in high-voltage alternating current (HVAC) transmission line projects across multiple continents. Before that, he held the position of Lead Energy Trade Commissioner in Washington, D.C., supporting the growth of Canadian clean energy exports to the United States. With more than 15 years of experience spanning the banking and energy sectors, Mr. Girard has advised multinational corporations, government agencies, and innovative start-ups. He also serves as an Adjunct Faculty Professor at the U.S. Foreign Service Institute (FSI), where he teaches courses on international energy markets and diplomacy. Mr. Girard holds an MBA from ESCP Europe and a bachelor's degree from McGill University. A global citizen, he has lived in eight countries and worked in more than 50. CTC Global welcomes Charles to the team as the company continues to expand its global impact and support utilities and nations working to modernize their power grids. About CTC Global: CTC Global is accelerating access to energy as the world's leading manufacturer of high-capacity advanced conductors. For over two decades, CTC Global has helped communities meet their energy needs and manage the risks associated with legacy transmission infrastructure. Today, over 300 utilities and industrial customers in over 65 countries and 30 U.S. states trust CTC to safely and quickly deploy solutions that add the greatest amount of electricity at the lowest capital cost. Headquartered in Irvine, California, over half of CTC Global's manufacturing capacity is U.S.-based. Its global operations are supported by five manufacturing facilities and an extensive network of partners around the world. CTC Global's advanced conductor is the most responsible and innovative solution to double capacity and improve reliability at scale. For more information, visit
